The Q3 earnings decline is largely attributed to M&A-related expenses and lower volumes in Performance Coatings, but the deal narrative remains unchanged. Watch for the AkzoNobel EGM on November 30, 2026, and any further regulatory updates as the Q1 2027 close target approaches.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Oct 29 $34.07entry
- T+1 · 6d ago +5.20%α +5.67% · $35.84
- T+5 · due 11h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Axalta filed two 425 communications on October 29, 2026: an investor presentation excerpt and an excerpt of its Q3 2026 earnings release, both in connection with the pending merger of equals with AkzoNobel. The Q3 results show net income down $15M YoY to $95M, diluted EPS of $0.44 versus $0.51, and adjusted net income down 6% to $136M, partly due to $14M in incremental M&A expenses. The filings reaffirm deal progress with no changes to terms or timeline, consistent with prior guidance of a Q1 2027 close.
Key Financial Metrics
Key Facts
- Q3 2026 net income decreased $15M YoY to $95M, net income margin 7.2%
- Diluted EPS $0.44 vs $0.51 in prior-year period
- Adjusted net income (ex-M&A expenses) decreased 6% YoY to $136M
- Free cash flow increased 3% YoY to $92M, including ~$21M of incremental M&A cash costs
- Cash from operations was $135M, in line with prior year
- Shareholders of both companies voted in favor of all merger resolutions on August 5, 2026
- Deal remains on track to close in early 2027 (Q1 2027 per prior filings)
- Two small remedy divestitures identified with combined revenue <EUR500M
- $600M cost synergy target reaffirmed as independent of remedies
- AkzoNobel EGM to approve name change and board appointments set for November 30, 2026
Financial Impact
Q3 net income down $15M YoY to $95M; EPS down $0.07 to $0.44; adjusted net income down 6% to $136M; free cash flow up 3% to $92M
Risk Factors
- Regulatory approvals not yet fully secured; two remedy divestitures required
- Q3 revenue and earnings declined YoY, indicating underlying operational headwinds
- Merger integration and synergy realization risks post-close
- Potential for competing offers or shareholder opposition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (AXTA), Batch item 1 | 0001193125-26-438072 |
| Document: 0001193125-26-438072-index-headers.html | 0001193125-26-438075 |
| Document: 0001193125-26-438072-index.html | 0001193125-26-438072 |
| Document: 0001193125-26-438072.txt | 0001193125-26-438072 |
| 425 Filing (AXTA), Batch item 5 | 0001193125-26-438075 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 7d ago | 425 | $34.07 $35.84 | ▼ −5.20% | ▼ −5.67% | $36.34 (−6.66%) |
Oct 29, 2026 7d ago | 425 | $34.07 $35.84 | ▲ +5.20% | ▲ +5.67% | $36.34 (+6.66%) |
Oct 29, 2026 7d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Oct 29, 2026 7d ago | Press Release | $33.61 $34.07 | ▼ −1.37% | ▼ −3.14% | $36.34 (−8.12%) |
Oct 21, 2026 15d ago | 425 | $34.98 $35.05 | ▲ +0.20% | ▲ +1.38% | $36.34 (+3.89%) |
Oct 21, 2026 15d ago | 425 | $34.98 $35.05 | ▲ +0.20% | ▲ +1.38% | $36.34 (+3.89%) |
Oct 20, 2026 16d ago | 425 | $34.98 $35.05 | ▲ +0.20% | ▲ +1.38% | $36.34 (+3.89%) |
Oct 16, 2026 20d ago | 425 | $33.44 $33.68 | ▲ +0.72% | ▲ +0.29% | $36.34 (+8.67%) |
Oct 15, 2026 21d ago | 425 | $33.44 $33.68 | ▲ +0.72% | ▲ +0.29% | $36.34 (+8.67%) |
Oct 15, 2026 21d ago | 425 | $33.44 $33.68 | ▲ +0.72% | ▲ +0.29% | $36.34 (+8.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers